Treatment with Tapentadol in Cancer Patients
Not Applicable
- Conditions
- Health Condition 1: G893- Neoplasm related pain (acute) (chronic)
- Registration Number
- CTRI/2020/11/029206
- Lead Sponsor
- Manipal Academy of Higher Education
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients of age >18 years and <70 years, from either sex.
Patients with moderate to severe pain {pain >4 measured on numerical rating scale (NRS)}.
Willing to participate in the study and provide written informed consent.
Exclusion Criteria
Pregnant/lactating women.
Patients already on MAO inhibitors, serotonin reuptake inhibitors, and Tricyclic antidepressants [contraindicated drugs].
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A treatment algorithm for Tapentadol therapy for pain management in palliative cancer patientsTimepoint: 3 years
- Secondary Outcome Measures
Name Time Method Pharmacogenomic profile and Population Pharmacokinetic model of TapentadolTimepoint: 3 years